Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong

References

• Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. http://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib/en/ Accessed 17 May 2015
   Google Scholar
• O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374:893-902; PMID:19748398; http://dx.doi.org/10.1016/S0140-6736(09)61204-6
   PubMed Web of Science ®Google Scholar
• Le CF, Jefferies JM, Yusof MY, Sekaran SD, Clarke SC. The epidemiology of pneumococcal carriage and infections in Malaysia. Expert Rev Anti Infect Ther 2012; 106:707-19; PMID:22734960; http://dx.doi.org/10.1586/eri.12.54
   PubMed Web of Science ®Google Scholar
• Centre for Health Protection. Frequently asked questions on pneumoccocal infection and pneumoccocal vaccines. http://www.chp.gov.hk/files/pdf/faqs_on_pneumoccocal_infection_and_pneumoccocal_vaccines.pdf Accessed 2 May 2015
   Google Scholar
• Bravo LC, Asian strategic alliance for pneumococcal disease prevention working G. Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine 2009; 27:7282-91; PMID:19393708; http://dx.doi.org/10.1016/j.vaccine.2009.04.046
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices (ACIP). Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49(RR9):1-35
   Google Scholar
• Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2012; 31:501-8; PMID:22327872; http://dx.doi.org/10.1097/INF.0b013e31824de9f6
   PubMed Web of Science ®Google Scholar
• CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease–United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7; PMID:16163262
   PubMedGoogle Scholar
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
   PubMed Web of Science ®Google Scholar
• Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63; PMID:23841730; http://dx.doi.org/10.1056/NEJMoa1209165
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011; 2:e00309-10; PMID:21264063; http://dx.doi.org/10.1128/mBio.00309-10
   PubMed Web of Science ®Google Scholar
• EMA. Synflorix: Summary of product characteristics. 2009.
   Google Scholar
• Wyeth submits marketing application to FDA for its 13-valent vaccine for the prevention of pneumococcal disease in infants and toddlers. 31 March 2009. http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressreleases/2009/1238506420199.html Accessed 2 March 2009
   Google Scholar
• Aljunid S, Abuduxike G, Ahmed Z, Sulong S, Nur AM, Goh A. Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia. BMC Infect Dis 2011; 11:248; PMID:21936928; http://dx.doi.org/10.1186/1471-2334-11-248
   PubMed Web of Science ®Google Scholar
• Lee KKC, Rinaldi F, Chan MKU, Chan STH, So TMT, Hon EKL, Lee VWY. Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong. Value in Health 2009; 12:S42-S8; PMID:20586981; http://dx.doi.org/10.1111/j.1524-4733.2009.00626.x
   PubMed Web of Science ®Google Scholar
• WHO. Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Weekly Epidemiological Record 2007; 82:93-104
   PubMedGoogle Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760-8; PMID:21621466; http://dx.doi.org/10.1016/S1473-3099(11)70090-1
   PubMed Web of Science ®Google Scholar
• Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine 2011; 29:6686-94; PMID:21745516; http://dx.doi.org/10.1016/j.vaccine.2011.06.091
   PubMed Web of Science ®Google Scholar
• Kulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett HC, Meeyai A, Punpanich W, Teerawattananon Y. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine 2013; 31:2839-47; PMID:23588084; http://dx.doi.org/10.1016/j.vaccine.2013.03.047
   PubMed Web of Science ®Google Scholar
• Aljunid S, Maimaiti N, Ahmed Z, Nur AM, Isa ZM, Azmi S, Sulong S. Economic impact of pneumococcal protein-D conjugate vaccine (PHiD-CV) on the Malaysian national immunization programme. Value in Health Regional Issues 2014; 3:146-55; http://dx.doi.org/10.1016/j.vhri.2014.04.008
   PubMedGoogle Scholar
• van Westen E, Wijmenga-Monsuur AJ, van Dijke HH, van Gaans-van den Brink JA, Kuipers B, Knol MJ, Berbers GA, Sanders EA, Rots NY, van Els CA. Differential B cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. Forthcoming 2015
   Google Scholar
• See comment in PubMed Commons below Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR. Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines 2012; 11:1235-47; PMID:23170992; http://dx.doi.org/10.1586/erv.12.99
   PubMed Web of Science ®Google Scholar
• Farkouh RA, Hall-Murray C, Klok RM, Hilton B, Isturiz RE. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal vaccine in Japanese children [Comment]. Infect Dis Ther 2015:1-7
   PubMedGoogle Scholar
• Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden [Letter to the editor]. Clin Ther 2013; 35:1048-50; PMID:23806326; http://dx.doi.org/10.1016/j.clinthera.2013.05.010
   PubMed Web of Science ®Google Scholar
• Strutton D, Hwang S, Farkouh R, Roberts C. Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries [Response]. Vaccine 2011; 29:7591-2; PMID:21406264; http://dx.doi.org/10.1016/j.vaccine.2011.02.103
   PubMed Web of Science ®Google Scholar
• van den Bergh MR, Spijkerman J, Swinnen KM, Francois NA, Pascal TG, Borys D, Schuerman L, Ijzerman EP, Bruin JP, van der Ende A, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013; 56:e30-9; PMID:23118268; http://dx.doi.org/10.1093/cid/cis922
   PubMed Web of Science ®Google Scholar
• Prymula R, Irena H, Miroslav S, Kriz P, Motlova J, Lebedova V, Lommel P, Kaliskova E, Pascal T, Borys D, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine 2011; 29:1959-67; PMID:21215830; http://dx.doi.org/10.1016/j.vaccine.2010.12.086
   PubMed Web of Science ®Google Scholar
• Prymula R, Habib A, François N, Borys D, Schuerman L. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine 2013; 31:2080-8; PMID:23391599; http://dx.doi.org/10.1016/j.vaccine.2013.01.044
   PubMed Web of Science ®Google Scholar
• Palmu AA, Jokinen J, Borys D, Nieminen H, Ruokokoski E, Siira L, Puumalainen T, Lommel P, Hezareh M, Moreira M, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381:214-22; PMID:23158882; http://dx.doi.org/10.1016/S0140-6736(12)61854-6
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Seppä I, Puumalainen T, Soininen A, Lommel P, Hezareh M, Moreira M, Borys D, Schuerman L. Effectiveness of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media. ICAAC 2012 (Abstract). San Francisco, CA, September 9–12, 2012.
   Google Scholar
• Sáez-Llorens X, Castrejon M, Rowley S, Wong D, Calvo A, Rodriguez M, Troitino M, Lommel P, Hausdorff W, Borys D. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) against acute otitis media in children in Panama. Poster presentation. The 9th International Symposium on Antimicrobial Agents and Resistance (ISAAR) March 13–15, Kuala Lumpur, Malaysia.
   Google Scholar
• Arguedas A, Soley C. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study [Comment]. Lancet 2006; 367:1898; PMID:16765750; http://dx.doi.org/10.1016/S0140-6736(06)68833-8
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Evaluation of effectiveness of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A against invasive disease. Study No.: 111442 (10PN-PD-DIT-043) 2013. Unpublished report.
   Google Scholar
• Moore M, Link-Gelles R, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison L, Lexau C, Zansky S, Petit S, Gershman K, et al. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease, U.S, 2010-11. ID Week 2012. https://idsa.confex.com/idsa/2012/webprogram/Paper36569.html Accessed 20 January 2013
   Google Scholar
• Health Protection Agency. Cumulative weekly number of reports of Invasive Pneumococcal Disease due to any of the six serotypes in Prevenar13™ but not in PCV7: persons aged >5 Years in England and Wales by Epidemiological Year: July-June (2005 – To Date). http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/InPrevenar13NotInPrevenarPCV7/pneumo09Cummulativeweekly5IN13NOTIN7vacc/ Accessed 15 July 2013
   Google Scholar
• Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Mason EO Jr. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203-7; PMID:23558320; http://dx.doi.org/10.1097/INF.0b013e318275614b
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011; 29:9127-31; PMID:21983361; http://dx.doi.org/10.1016/j.vaccine.2011.09.112
   PubMed Web of Science ®Google Scholar
• Domingues CM, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone MC, Flannery B, de Oliveira LH, Santos JB, de Moraes JC; Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2014; 2:464-71; PMID:24726406; http://dx.doi.org/10.1016/S2213-2600(14)70060-8
   PubMed Web of Science ®Google Scholar
• Pan American Health Organization. Informe Regional de SIREVA II, 2006: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores. Washington DC: Pan American Health Organization; 2008.
   Google Scholar
• Pan American Health Organization. Informe Regional de SIREVA II, 2011: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores. Washington DC: Pan American Health Organization; 2012.
   Google Scholar
• National Institute for Health and Welfare. Incidence of invasive pneumococcal disease in Finland. https://www.thl.fi/fi/web/thlfi-en/topics/information-packages/incidence-of-invasive-pneumococcal-disease-in-finland Accessed 27 January 2015
   Google Scholar
• Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368:1495-502; PMID:17071283; http://dx.doi.org/10.1016/S0140-6736(06)69637-2
   PubMed Web of Science ®Google Scholar
• De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, Farley MM, Harrison LH, Lynfield R, Bennett NM, et al. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine 2012; 30:4067-72; PMID:22525797; http://dx.doi.org/10.1016/j.vaccine.2012.04.017
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28: S66-76; PMID:19325449; http://dx.doi.org/10.1097/INF.0b013e318199f8ef
   PubMed Web of Science ®Google Scholar
• Institute of Environmental Science and Research Ltd (ESR). Invasive pneumococcal disease in New Zealand, 2013. https://surv.esr.cri.nz/PDF_surveillance/IPD/2013/2013AnnualIPDRpt.pdf Accessed 17 May 2015
   Google Scholar
• Davis SM, Deloria-Knoll M, Kassa HT, O'Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 2013; 32:133-45; PMID:23684824; http://dx.doi.org/10.1016/j.vaccine.2013.05.005
   PubMed Web of Science ®Google Scholar
• Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010; 29:607-12; PMID:20589980; http://dx.doi.org/10.1097/INF.0b013e3181d7d09c
   PubMed Web of Science ®Google Scholar
• Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J 2012; 31:297-301; PMID:22330166; http://dx.doi.org/10.1097/INF.0b013e318247ef84
   PubMed Web of Science ®Google Scholar
• Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R, Alemán J, Hudgens MG, Woods CW, Weber DJ. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J 2014; 33:637-42; PMID:24445827; http://dx.doi.org/10.1097/INF.0000000000000269
   PubMed Web of Science ®Google Scholar
• Guevara M, Ezpeleta C, Gil-Setas A, Torroba L, Beristain X, Aguinaga A, García-Irure JJ, Navascués A, García-Cenoz M, Castilla J, et al. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain,2001–2013. Vaccine 2014; 32:2553-62; PMID:24674661; http://dx.doi.org/10.1016/j.vaccine.2014.03.054
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis 2014; 59:1066-73; PMID:25034421; http://dx.doi.org/10.1093/cid/ciu524
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D, Microbiologists of Epibac, ORP Networks. Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine 2015; 33:359-66; PMID:25448105; http://dx.doi.org/10.1016/j.vaccine.2014.11.011
   PubMed Web of Science ®Google Scholar
• Lim GH, Wormsbecker AE, McGeer A, Pillai DR, Gubbay JB, Rudnick W, Low DE, Green K, Crowcroft NS, Deeks SL. Have changing pneumococcal vaccination programmes impacted disease in Ontario? Vaccine 2013; 31:2680-5; PMID:23597716; http://dx.doi.org/10.1016/j.vaccine.2013.04.007
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301-9; PMID:25656600; http://dx.doi.org/10.1016/S1473-3099(14)71081-3
   PubMed Web of Science ®Google Scholar
• Regev-Yochay G, Paran Y, Bishara J, Oren I, Chowers M, Tziba Y, Istomin V, Weinberger M, Miron D, Temper V, et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine 2015; 33:1135-42; PMID:25613717; http://dx.doi.org/10.1016/j.vaccine.2015.01.030
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med 2014; 2:387-94; PMID:24815804; http://dx.doi.org/10.1016/S2213-2600(14)70032-3
   PubMed Web of Science ®Google Scholar
• Ho PL, Chiu SS, Cheung CH, Lee R, Tsai TF, Lau YL. Invasive pneumococcal disease burden in Hong Kong children. Pediatr Infect Dis J 2006 May; 25:454-5; PMID:16645513; http://dx.doi.org/10.1097/01.inf.0000215004.85582.30
   PubMed Web of Science ®Google Scholar
• Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010; 28:7634-43; PMID:20883739; http://dx.doi.org/10.1016/j.vaccine.2010.09.049
   PubMed Web of Science ®Google Scholar
• The Center's for Disease Control and Prevention Active Bacterial Core Surveillance (ABCs) program 2009. Unpublished report.
   Google Scholar
• Population estimates from Malaysia Census and Statistics Department. www.statistics.gov.my/portal/download_Population/files/census2010/Taburan_Penduduk_dan_Ciri-ciri_Asas_Demografi.pdf Accessed 23 June 2013
   Google Scholar
• Population estimates from Hong Kong Census and Statistics Department. http://www.censtatd.gov.hk/hong_kong_statistics/statistical_tables/index.jsp?charsetID=1&subjectID=1&tableID=152 Accessed 23 June 2013
   Google Scholar
• WHO. Malaysia: WHO and UNICEF estimates of immunization coverage: 2013 revision. http://www.who.int/immunization/monitoring_surveillance/data/mys.pdf Accessed 17 May 2015
   Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR; ISPOR Task Force on Good Research Practices–Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 2003; 6:9-17; PMID:12535234; http://dx.doi.org/10.1046/j.1524-4733.2003.00234.x
   PubMed Web of Science ®Google Scholar
• Hsieh YC, Lin PY, Chiu CH, Huang YC, Chang KY, Liao CH, Chiu NC, Chuang YC, Chen PY, Chang SC, et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009; 27:5513-8; PMID:19615960; http://dx.doi.org/10.1016/j.vaccine.2009.06.091
   PubMed Web of Science ®Google Scholar
• Maimaiti N, Aljunid S, Ahmed Z, Nur AM, Isa ZM, Sulung S. Clinical burden of pneumococcal disease in Malaysia APCP 2012 (Abstract). Kuching, Malaysia, 2012.
   Google Scholar
• Wu DB, Chang CJ, Huang YC, Wen YW, Wu CL, Fann CS. Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach. Value Health 2012; 15: S15-9; PMID:22265061; http://dx.doi.org/10.1016/j.jval.2012.03.1391
   PubMed Web of Science ®Google Scholar
• Sung RYT, Yu CW, Chan JTS. How common is acute otitis media in Hong Kong? HK Pract 2003; 20:114-9
   Google Scholar
• Lin TY, Shah NK, Brooks D, Garcia CS. Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region. Vaccine 2010; 28:7589-605; PMID:20674872; http://dx.doi.org/10.1016/j.vaccine.2010.07.053
   PubMed Web of Science ®Google Scholar
• Low S, Chan FL, Cutter J, Ma S, Goh KT, Chew SK. A national study of the epidemiology of pneumococcal disease among hospitalised patients in Singapore: 1995 to 2004. Singapore Med J 2007; 48:824-9; PMID:17728963
   PubMedGoogle Scholar
• Sirinavin S, Vorachit M, Thakkinstian A, Hongsanguensri S, Wittayawongsruji P. Pediatric invasive pneumococcal disease in a teaching hospital in Bangkok. Int J Infect Dis 2003; 7:183-9; PMID:14563221; http://dx.doi.org/10.1016/S1201-9712(03)90050-6
   PubMedGoogle Scholar
• Wardlaw TM, Johansson EW, Hodge M, UNICEF/WHO. Pneumonia: the forgotten killer of children. 2006.
   Google Scholar
• Ahmed Z, Aljunid S, Maimaiti N, Nur AM, Isa ZM, Sulung S. Economic burden of pneumococcal disease in Malaysia. APCP 2012 (abstract). Kuching, Malaysia, 2012.
   Google Scholar
• Total expenditure in Malaysia. Available at http://www.who.int/countries/mys/en/ Accessed 14 Oct 2012.
   Google Scholar
• Total expenditure in the US. Available at http://www.who.int/countries/usa/en/ Accessed 14 Oct 2012.
   Google Scholar
• Nakamura MM, Tasslimi A, Lieu TA, Levine OS, Knoll MD, Russell LB, Sinha A. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. Int Health 2011; 3:270-81; PMID:24038500; http://dx.doi.org/10.1016/j.inhe.2011.08.004
   PubMed Web of Science ®Google Scholar
• Malaysian Investment Development Authority. Available at www.mida.gov.my/env3/index.php?page=wage-rates. Accessed 10 May 2013.
   Google Scholar
• Wages and Labour Earnings 2011. http://www.censtatd.gov.hk/m/o210.jsp. Accessed 13 May 2013.
   Google Scholar
• Department of Statistics Malaysia, official portal 2012. www.statistics.gov.my Accessed 13 May 2013.
   Google Scholar
• Census and Statistics Department. www.censtatd.gov.hk/hkstat/sub/sp270.jsp Accessed 13 May 2013.
   Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95; PMID:10749457; http://dx.doi.org/10.1097/00006454-200003000-00003
   PubMed Web of Science ®Google Scholar
• Jauneikaite E, Jefferies JM, Hibberd ML, Clarke SC. Prevalence of Streptococcus pneumoniae serotypes causing invasive and non-invasive disease in South East Asia: a review. Vaccine 2012; 30:3503-14; PMID:22475858; http://dx.doi.org/10.1016/j.vaccine.2012.03.066
   PubMed Web of Science ®Google Scholar
• Ho PL, Chiu SS, Ang I, Lau YL. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae before and after introduction of 7-valent pneumococcal conjugate vaccine, Hong Kong, 1995-2009. Vaccine 2011; 29:3270-5; PMID:21352937; http://dx.doi.org/10.1016/j.vaccine.2011.02.025
   PubMed Web of Science ®Google Scholar
• Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J 2006; 25:779-81; PMID:16940833; http://dx.doi.org/10.1097/01.inf.0000232706.35674.2f
   PubMed Web of Science ®Google Scholar
• Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003; 22:10-6; PMID:12544402; http://dx.doi.org/10.1097/00006454-200301000-00006
   PubMed Web of Science ®Google Scholar
• Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, Miller MA, Shinefield HR. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 2000; 283:1460-8; PMID:10732936; http://dx.doi.org/10.1001/jama.283.11.1460
   PubMed Web of Science ®Google Scholar
• Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006; 25:494-501; PMID:16732146; http://dx.doi.org/10.1097/01.inf.0000222403.42974.8b
   PubMed Web of Science ®Google Scholar
• Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch Pediatr Adolesc Med 2007; 161:1162-8; PMID:18056561; http://dx.doi.org/10.1001/archpedi.161.12.1162
   PubMed Web of Science ®Google Scholar
• Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008; 121:253-60; PMID:18245415; http://dx.doi.org/10.1542/peds.2007-0619
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369:1179-86; PMID:17416262; http://dx.doi.org/10.1016/S0140-6736(07)60564-9
   PubMed Web of Science ®Google Scholar
• Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8; PMID:16517274; http://dx.doi.org/10.1016/S0140-6736(06)68304-9
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004; 22:4203-14; PMID:15474710; http://dx.doi.org/10.1016/j.vaccine.2004.05.003
   PubMed Web of Science ®Google Scholar
• Shepard CW, Ortega-Sanchez IR, Scott II RD, Rosenstein NE, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005; 115:1220-32; PMID:15867028; http://dx.doi.org/10.1542/peds.2004-2514
   PubMed Web of Science ®Google Scholar
• Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis 2001; 33:737-9; PMID:11477523; http://dx.doi.org/10.1086/322587
   PubMed Web of Science ®Google Scholar
• Oostenbrook R, Moll H, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002; 55:791-99; PMID:12384194; http://dx.doi.org/10.1016/S0895-4356(02)00448-1
   PubMed Web of Science ®Google Scholar
• World Health Organization Cost-effectiveness Threshold Values. Available from: www.who.int/choice/en/. Accessed 10 May 2013.
   Google Scholar
• Malaysian and Hong Kong GDP per capita 2011. Available from: http://en.wikipedia.org/wiki/List_of_countries_by_GDP_(nominal)_per_capita. Accessed 10 May 2013.
   Google Scholar